San Diego-dependent Viking Therapeutics marked by itself as a serious competitor from the weight loss drug market place in February right after revealing promising details from a mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the compa